During Thursday’s Current trade, Shares of Esperion Therapeutics Inc (NASDAQ:ESPR), gain 2.19% to $98.80.
Esperion Therapeutics, Inc. (ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, recently declared the U.S. Food and Drug Administration (FDA) has removed the 240 mg partial clinical hold on ETC-1002 (bempedoic acid.
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products comprise ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, in addition to to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies. .
Shares of Nielsen NV (NYSE:NLSN), inclined 0.33% to $45.71, during its current trading session.
Nielsen NV (NLSN) declared that Eric Dale will be the company’s new Chief Legal Officer effective Aug. 1, 2015. Dale joins the company from Robinson & Cole LLP where he was a partner.
Dale has spent more than 20 years assisting to build, manage and structure global companies.
Nielsen N.V. operates as an information and measurement company. The company provides media and marketing information, analytics, and manufacturer and retailer expertise about what and where consumers buy, read, watch and listen. Its Buy segment provides data on retail measurement services, such as market share and competitive sales volumes; insights into distribution, pricing, merchandising, and promotion; consumer panel measurement, which offers insight into shopper behavior and customer segmentation; and consumer intelligence and analytical services for decision making in development and marketing cycles.
HCP, Inc. (NYSE:HCP), during its Thursday’s current trading session gained 0.35% to $37.58.
HCP (HCP) will report its second quarter 2015 financial results on Tuesday, August 4, 2015, before the open of trading on the New York Stock Exchange. HCP will also host a conference call and webcast at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) that same day in order to review its financial performance and operating results for the quarter ended June 30, 2015.
HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry counting sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing.
Finally, DBV Technologies SA – ADR (NASDAQ:DBVT), decreased -0.89%, to $41.14.
DBV Technologies (DBVT), a clinical-stage specialty biopharmaceutical company, declared the pricing of an underwritten public offering of 3,600,000 ordinary shares in the form of 7,200,000 American Depositary Shares, or ADSs, at a price to the public of $34.00 per ADS, before underwriting discounts and commissions. Each ADS represents the right to receive one-half of one ordinary share.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company provides Diallertest Milk, a diagnostic product for the detection of cow’s milk protein allergy (CMPA) in children.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
